© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
HOOKIPA Pharma Inc. (HOOK) stock declined over -0.25%, trading at $3.98 on NASDAQ, down from the previous close of $3.99. The stock opened at $4.08, fluctuating between $3.95 and $4.13 in the recent session.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Employees | 151 |
Beta | 0.832 |
Sales or Revenue | $20.13M |
5Y Sales Change% | 3.556% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
HOOKIPA Pharma Inc. (NASDAQ: HOOK) stock price is $3.98 in the last trading session. During the trading session, HOOK stock reached the peak price of $4.13 while $3.95 was the lowest point it dropped to. The percentage change in HOOK stock occurred in the recent session was -0.25% while the dollar amount for the price change in HOOK stock was -$0.01.
The NASDAQ listed HOOK is part of Biotechnology industry that operates in the broader Healthcare sector. HOOKIPA Pharma Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Andreas Bergthaler
Co-Founder
Mr. Jorn Aldag
Chief Executive Officer & Director
Mr. Joern Aldag
Chief Executive Officer & Director
Prof. Rolf M. Zinkernagel M.D., Ph.D.
Co-Founder
Dr. Roman Necina Ph.D.
Chief Devel. Officer
Dr. Reinhard Kandera Ph.D.
Chief Financial Officer & Director
Mr. Michael Szumera
Executive Director of Communications
Ms. Christine D. Baker M.B.A.
Chief Operating Officer
Ms. Marine Popoff
Communications & Investor Relations Mang.
Dr. Klaus Orlinger Ph.D.
Chief Scientific Officer
Mr. Lukas Flatz
Co-Founder
Mr. Matthew L. S. Beck
Executive Director of Investor Relations
HOOK's closing price is 16.55% higher than its 52-week low of $3.42 where as its distance from 52-week high of $11.30 is -64.78%.
Number of HOOK employees currently stands at 151.
Official Website of HOOK is: https://www.hookipapharma.com
HOOK could be contacted at phone 431 890 6360 and can also be accessed through its website. HOOK operates from 350 Fifth Avenue, New York, NY 10118, United States.
HOOK stock volume for the day was 33.45K shares. The average number of HOOK shares traded daily for last 3 months was 28.24K.
The market value of HOOK currently stands at $47.98M with its latest stock price at $3.98 and 12.05M of its shares outstanding.